Working… Menu

Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02369731
Recruitment Status : Recruiting
First Posted : February 24, 2015
Last Update Posted : February 14, 2017
Cooperative International Neuromuscular Research Group
Information provided by (Responsible Party):
PTC Therapeutics

Brief Summary:
This study is being performed as a post-approval safety study (PASS), per the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA), to gather data on Translarna (ataluren) safety, effectiveness, and prescription patterns in routine clinical practice.

Condition or disease Intervention/treatment
Muscular Dystrophy, Duchenne Drug: Translarna

Detailed Description:
This is a multicenter, observational study of patients receiving Translarna based on inclusion of their data in a registry. This study is intended to enroll 200 patients across ~50 care centers in Europe and other regions over a period of ~ 2 years. The study population will include patients who are receiving usual care treatment with commercial supply of Translarna (or receiving care within a named patient early access program) and who provide consent. Patients will be followed for at least 5 years from their date of enrollment. Safety and efficacy data will be collected in conjunction with routine visits conducted as per usual care. Although there are no protocol-mandated procedures, it is expected that physicians and other caregivers will follow published treatment guidelines and standards of care.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 200 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: Long-Term Observational Study of Translarna Safety and Effectiveness in Usual Care
Study Start Date : April 2015
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : April 2022

Intervention Details:
  • Drug: Translarna
    Other Names:
    • Ataluren
    • PTC124

Primary Outcome Measures :
  1. Incidence of adverse events [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. Changes in laboratory parameters [ Time Frame: 5 years ]
  2. Changes in blood pressure [ Time Frame: 5 years ]
  3. Prescriber and patient compliance with prescribing information according to the approved labelling [ Time Frame: 5 years ]

Other Outcome Measures:
  1. Patient health management measures [ Time Frame: 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The target study population will include patients for whom the decision to prescribe Translarna (outside of a clinical trial) has already been made, including patients in named patient early access programs. Patients within each prescriber's practice who are or will be receiving treatment with Translarna, and who meet the eligibility criteria and provide informed consent (either by the patient or through authorisation by a legal guardian), will be invited to enroll into the study and will be followed according to the protocol.

Inclusion Criteria:

  • Receiving or will be receiving usual care treatment with commercial supply of Translarna (or receiving care within a named patient early access program)
  • Willing to provide written informed consent to allow the study data collection procedures (either by the patient or through authorisation by a legal guardian)

Exclusion Criteria:

  • Patients who are receiving ataluren or placebo in a blinded, randomized clinical trial, or ataluren in any other ataluren clinical trial or cohort early access program that prevents participation in this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02369731

Layout table for location contacts
Contact: Abdallah Delage

Layout table for location information
Krankenhaus der Barmherzigen Schwestern Linz Recruiting
Linz, Austria, 4010
Principal Investigator: Veronika Pilshofer, Dr         
Preyer Children Hospital Recruiting
Wien, Austria, 1100
Principal Investigator: Guenther Bernert, Pr         
CHU Brest, hôpital Morvan Recruiting
Best, France, 29609
Principal Investigator: Ropars Juliette, Dr         
CHU Bordeaux Pelgrin Recruiting
Bordeaux Cedex, France, 33076
Principal Investigator: Caroline Espil-Taris         
L'Escale Hôpital Femme Mère Enfant- Hospices Civils de Lyon Recruiting
Bron, France, 69500
Principal Investigator: Carole Vuillerot, Dr         
CHU Clermont-Ferrand, hôpital Estaing Recruiting
Clermont-Ferrand, France, 63003
Principal Investigator: Catherine Sarret, Dr         
CHU de Martinique - Hôpital P. Zobda-Quitman Recruiting
Fort De France Cedex, France, 97261
Principal Investigator: Rémi Bellance, Dr         
CHRU de Lille Recruiting
Lille Cedex, France, 59037
Principal Investigator: Jean-Marie Cuisset, Dr         
CHU Marseille Hôpital de la Timone Recruiting
Marseille Cedex 5, France, 13385
Principal Investigator: Brigitte Chabrol, Pr         
CHU Nantes Recruiting
Nantes, France, 44000
Principal Investigator: Yan Pereon, Pr         
Hôpital Armand Trousseau Recruiting
Paris, France, 75012
Principal Investigator: Gidaro Teresa, Dr         
Hôpital Necker Recruiting
Paris, France, 75015
Principal Investigator: Isabelle Desguerre, Pr         
CHU Reims Recruiting
Reims, France, 51100
Principal Investigator: Pascal Sabouraud, Dr         
CHU Saint-Etienne MPR pédiatrique Hôpital Bellevue Recruiting
Saint Etienne Cedex, France, 42055
Principal Investigator: Stéphane Chabrier, Dr         
CHU de la Réunion - GHSR - GH Sud-Réunion Recruiting
Saint Pierre, France, 97448
Principal Investigator: Renouil Michel, Dr         
CHU Strasbourg Recruiting
Strasbourg Cedex, France, 67098
Principal Investigator: Vincent Laugel, Pr         
CHU Toulouse Recruiting
Toulouse, France, 31059
Principal Investigator: Pascal Cintas, Dr         
Hôpital d'enfants Gatien de Clocheville Recruiting
Tours Cedex 9, France, 37044
Principal Investigator: Lagrue Emmanuelle, Dr         
CHU Nancy Hôpital de Brabois-Enfants Rue du Morvan Recruiting
Vandoeuvre-les-Nancy, France, 54500
Principal Investigator: Emmanuel Raffo, Pr         
Klinikum Bayreuth GmbH Recruiting
Bayreuth, Germany, 95445
Principal Investigator: Almut Hirsch, Dr         
Charité Universitätsmedizin Berlin Recruiting
Berlin, Germany, 13353
Principal Investigator: Claudia Weiss, Dr         
Universitätsklinikum Erlangen Recruiting
Erlangen, Germany, 91054
Principal Investigator: Regina Trollmann, Pr         
Universitaetsklinikum Essen (AoR) Recruiting
Essen, Germany, 45147
Principal Investigator: Ulrike Schara, Pr         
SPZ Frankfurt Mitte Recruiting
Frankfurt am Main, Germany, 60316
Principal Investigator: Jurgen Seeger, Dr         
Universitaetsklinikum Freiburg Recruiting
Freiburg, Germany, 79106
Principal Investigator: Janbernd Kirschner, Pr         
UKE, Universitätsklinikum Hamburg-Eppendorf Recruiting
Hamburg, Germany, 20246
Principal Investigator: Jessica Johannsen, Dr         
Hadassah Medical Center Recruiting
Jerusalem, Israel, 91120
Principal Investigator: Talya Dor, Dr         
Chaim Sheba Medical Center Ramat Gan, Neuromuscle clinic Recruiting
Ramat Gan, Israel, 52621
Principal Investigator: Amir Dori, Dr         
Queen Silvia Children's Hospital Recruiting
Goteborg, Sweden, 41685
Principal Investigator: Mar Tulinius, Pr         
Sponsors and Collaborators
PTC Therapeutics
Cooperative International Neuromuscular Research Group
Layout table for investigator information
Study Director: Robert Spiegel, MD PTC Therapeutics

Additional Information:

Layout table for additonal information
Responsible Party: PTC Therapeutics Identifier: NCT02369731     History of Changes
Other Study ID Numbers: PTC124-GD-025o-DMD
First Posted: February 24, 2015    Key Record Dates
Last Update Posted: February 14, 2017
Last Verified: February 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked